

Syncona Update

April 2021



Syncona

Building the next generation of healthcare companies

Key Announcements

[Syncona Appoints Kenneth Galbraith as Executive in Residence](#)

08.04.2021

Syncona announced the appointment of Kenneth Galbraith as Executive in Residence. Ken brings over 30 years' experience in biotechnology and venture capital and will work alongside the Syncona Investment Management Limited team to support portfolio companies as they scale and develop.

Martin Murphy, CEO, said: "We are pleased to expand our team with the appointment of Ken as Executive in Residence. He brings invaluable experience in both biotech company building and venture capital and will play an important role in supporting our portfolio companies as they scale. We look forward to working with him."

Key Media Coverage

[Covid's silver lining: clinical trials will be faster, better and cheaper](#)

The Telegraph 06.04.2021

In an article looking at the future of clinical trials post-Covid, Julia Bradshaw of The Telegraph spoke to Martin Murphy about current trends in trials. He said that "Many of these trends were happening anyway, it's just Covid has now demonstrated, like a proof of concept, that rolling reviews can work, that real-time data capture can work, that access to large data banks for trial designs can work, now we need to accelerate this as it's a valuable chance to improve clinical development by reducing timelines and cost. It would be a silver lining to the pandemic."

[Appointments and advancements for 8 April 2021](#)

BioWorld 08.04.2021

In its appointments column, BioWorld noted that Kenneth Galbraith joined Syncona as Executive in Residence.

[The science of getting rich: Investing in university spin-outs can help your profits grow](#)

Daily Mail 09.04.2021

In an article for the Daily Mail Anne Ashworth highlights Syncona as a company to invest in for access to university spin-outs in the life sciences sector.

Autolus

Developing next generation programmed T cell therapies for the treatment of cancer

Key Announcements

[Autolus Therapeutics Receives PRIME designation for AUTO1 for the treatment of adult ALL](#)

01.04.2021

Autolus announced that it has received PRiority Medicines (PRIME) designation from the European Medicines Agency (EMA) for AUTO1, the company's CAR T cell therapy being investigated in the ongoing FELIX Phase 1b/2 study in relapsed / refractory (r/r) adult B-Acute Lymphocytic Leukemia (ALL).

[Autolus: Developing Next Generation Programmed T Cell Therapies](#)

08.04.2021

Access Autolus' presentation on the development of next generation programmed T Cell therapies [here](#).

[Autolus appoints non-executive Chair](#)

19.04.2021

Autolus announced that Martin Murphy, CEO of Syncona, has been appointed as non-executive chairman of its Board of Directors, effective 15 April 2021. Martin said: "I am delighted to take up the role of chairman at Autolus at an important time in the company's development as it looks to progress AUTO1 through a pivotal Phase 1 study. I am excited about the company's potential and the opportunity to continue to support, and work alongside, Christian and Autolus' talented and experienced senior management team."

[Autolus Therapeutics Receives Innovation Passport and entry into ILAP for AUTO4 for the treatment of T cell receptor constant region beta chain 1 \(TRBC1\) positive T cell lymphomas](#)

20.04.2021

Autolus announced that it has received innovative licensing and access pathway (ILAP) designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for AUTO4 being studied in a Phase 1 study in TRBC1 positive Peripheral T Cell Lymphoma (PTCL).

[Autolus Therapeutics to Report First Quarter 2021 Financial Results on May 6](#)

26.04.2021

Autolus announced that it will release its first quarter 2021 financial results and operational highlights before open of US markets on Thursday, 6 May 2021.

Key Media Coverage

[Next-Gen CAR T & Novel SMA Drug Among New Entrants On EMA's PRIME](#)

Pink Sheet 15.04.2021

Neena Brizmohun of Pink Sheet writes that Autolus has managed to convince the European Medicines Agency that its investigational treatment AUTO1 merits a place on the regulator's priority medicines scheme.

[Weekly biopharma job report](#)

Endpoints News 23.04.2021

In its weekly biopharma job report, Endpoints News highlights Martin's appointment as Autolus Chair.

Freeline

Focused on developing curative gene therapies for chronic systemic diseases

Key Announcements

[Freeline Reports Financial Results and Business Highlights](#)

01.04.2021

Freeline reported financial results for the full year 2020 and provided an update on recent business highlights.

"We are pleased with our current progress and aim to have three Freeline programs in the clinic by the end of 2021," said Theresa Heggie, CEO. "We are looking forward to initiation of the Phase 1/2 dose-confirmation study for our lead program, FLT180a for the treatment of Haemophilia B, later this year to confirm both the dose and the immune management regimen for our planned pivotal Phase 3 study. Importantly, the data from the Phase 1/2 dose-finding trial we completed last year demonstrated the potential of FLT180a to provide a functional cure through the durable normalization of Factor IX activity. We also plan to progress dose escalation for the Phase 1/2 clinical study of FLT190 for the treatment of Fabry disease during 2021. Additionally, we are on track to dose the first patient in our FLT201 program for the treatment of Type 1 Gaucher disease by the end of 2021.

[Freeline to Participate in Upcoming Investor Conferences in April and May 2021](#)

22.04.2021

Freeline announced participation in the following virtual investor conferences:

- Chardan's 5th Annual Genetic Medicines Manufacturing Summit on 26 April 2021, where senior management will give a Company presentation at 9:45 am ET.
- 7th Annual Truist Securities 2021 Life Sciences Summit on 4 May 2021, where senior management will participate in virtual one-on-one meetings with investors.

The Company presentation from Chardan's 5th Annual Genetic Medicines Manufacturing Summit is available on the investors section of the Freeline website at [Freeline.life](https://www.freeline.life).

[Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021](#)

28.04.2021

Freeline announced that the Company will give six poster presentations at the American Society of Gene and Cell Therapy Annual Meeting 2021, taking place 11-14 May.

"We are excited to be presenting six posters at the upcoming ASGCT conference, which together highlight the scientific foundation that underlies our gene therapy programs and broader platform technology," said Theresa Heggie, CEO. "These posters are reflective of steady progress at Freeline, which we expect will include three gene therapies in the clinic by year end."

Gyroscope Therapeutics

Developing gene therapies and surgical delivery systems for retinal diseases

Key Announcements

[Gyroscope files registration statement for proposed initial public offering in the United States](#)

19.04.2021

Gyroscope filed a registration statement on Form F-1 with the US Securities and Exchange Commission relating to a proposed initial public offering (IPO) in the United States of its American Depositary Shares (ADSs), each representing one ordinary share of Gyroscope. All ADSs to be sold in the proposed IPO will be offered by Gyroscope. The number of ADSs to be offered and the pricing terms for the proposed IPO have not yet been determined.

[Update on Gyroscope Therapeutics' proposed IPO in the United States](#)

Gyroscope filed an amended registration statement on Form F-1 with the U.S. Securities and Exchange Commission.

The registration statement disclosed an indicative pricing range for the proposed offering of U.S. \$20.00 - \$22.00 per ADS. This would represent an increase in value of Syncona's current shareholding in Gyroscope (compared to the sterling holding value announced following the Series C financing on 26 March 2021) of £52-£72 million¹ (7.7p-10.7p per Syncona share). The proposed offering amount specified in the filing is 6,750,000 ADSs which at the midpoint of the indicative pricing range would result in gross proceeds to Gyroscope of approximately U.S. \$141.8 million and does not include the underwriters' option to purchase additional ADSs.

Key Media Coverage

[3 very different biotechs all file for the same IPO goal: A big raise on Nasdaq](#)

FierceBiotech 19.05.2021

Ben Adams of FierceBiotech noted that Gyroscope has joined the conga line for the biotech IPO boom. The Hertfordshire, UK-based company was founded in 2016 and is looking to tap the promise of a gene therapy approach to cure blindness, initially focusing on age-related macular degeneration (AMD).

Resolution Therapeutics

Developing macrophage cell therapies to repair organ damage, including treatment of end-stage chronic liver disease

Key Announcements

[Resolution Therapeutics Appoints Lisa Bright to its Board of Directors](#)

12.04.2021

Resolution announced the appointment of Lisa Bright as a Non-Executive Director of the Company. Lisa's appointment brings skills to the Board in strategic, commercial, and operational leadership in global market leading pharmaceutical and emerging biotech companies gained over her 30-year career in the industry.

Key Media Coverage

[Weekly biopharma job report](#)

Endpoints News 16.04.2021

In its weekly biopharma job report, Endpoints News noted that Resolution Therapeutics recruited Lisa Bright as non-executive director. Bright served as chief commercial and corporate affairs officer and later president international at Intercept. In addition, she held roles at Gilead, GSK and Ascendis Pharma among others.